Functional and molecular surveillance of Helicobacter pylori antibiotic resistance in Kuala Lumpur

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Teh, Xinsheng ^a   Khosravi, Yalda ^a   Lee, Woon Ching ^a   Leow, Alex Hwong Ruey ^a   Loke, Mun Fai ^a   Vadivelu, Jamuna ^a   Goh, Khean Lee ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CIPROFLOXACIN; CLARITHROMYCIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; GEMIFLOXACIN; LEVOFLOXACIN; METRONIDAZOLE; MOXIFLOXACIN; NITROFURANTOIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RNA 23S; TETRACYCLINE; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM EXAMINATION; BACTERIUM ISOLATE; DRUG MECHANISM; EPSILOMETER TEST; FRXA GENE; GASTROINTESTINAL DISEASE; GENE MUTATION; GENETIC VARIABILITY; GYRA GENE; GYRB GENE; HELICOBACTER PYLORI; MALAYSIA; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PREVALENCE; RDXA GENE; DRUG EFFECTS; GENETICS; HELICOBACTER INFECTIONS; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MUTATION;

ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE; FLUOROQUINOLONES; GENES, BACTERIAL; GENETIC VARIATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALAYSIA; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; MUTATION; PREVALENCE; RNA, RIBOSOMAL, 23S;

EID: 84903878969     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101481     Document Type: Article

References (51)

1. Dunn BE, Cohen H, Blaser MJ (1997) Helicobacter pylori. Clin Microbiol Rev 10: 720-741.
2. Dorer MS, Talarico S, Salama NR (2009) Helicobacter pylori's unconventional role in health and disease. PLoS Pathog 5: e1000544.
3. WHO (2011) Agents Classified by the IARC Monographs, Volumes 1-102. Cancer, World Health Organization.
4. Goh KL, Chan WK, Shiota S, Yamaoka Y (2011) Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter 16 Suppl 1: 1-9.
5. Tan HJ, Goh KL (2008) Changing epidemiology of Helicobacter pylori in Asia. Journal of Digestive Diseases 9: 186-189.
6. Wu CY, Kuo KN, Wu MS, Chen YJ, Wang CB, et al. (2009) Early Helicobacter pylori Eradication Decreases Risk of Gastric Cancer in Patients With Peptic Ulcer Disease. Gastroenterology 137: 1641-1648.
7. Malfertheiner P, Megraud F, O'Morain C, Bell D, Bianchi Porro G, et al. (1997) Current European concepts in the management of Helicobacter pylori infection-the Maastricht Consensus Report. The European Helicobacter pylori Study Group (EHPSG). Eur J Gastroenterol Hepatol 9: 1-2.
8. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon ATR, et al. (2012) Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut 61: 646-664.
9. Zullo A, De Francesco V, Vaira D (2011) Sequential therapy for Helicobacter pylori eradication: is levofloxacin better? Gut 60: 1604-1604.
10. Fischbach L, Evans EL (2007) Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Alimentary Pharmacology & Therapeutics 26: 343-357.
11. Megraud F (2012) The challenge of Helicobacter pylori resistance to antibiotics: the comeback of bismuth-based quadruple therapy. Therap Adv Gastroenterol 5: 103-109.
12. Gisbert JP (2008) Second-line rescue therapy with levofloxacin after H-pylori treatment failure: A Spanish multicenter study. Gastroenterology 134: A333-A333.
13. Katelaris PH, Forbes GM, Talley NJ, Crotty B (2002) A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study. Gastroenterology 123: 1763-1769.
14. Cuadrado-Lavin A, Salcines-Caviedes JR, Carrascosa MF, Mellado P, Monteagudo I, et al. (2012) Antimicrobial susceptibility of Helicobacter pylori to six antibiotics currently used in Spain. J Antimicrob Chemother 67: 170-173.
15. Chang WL, Kao CY, Wu CT, Huang AH, Wu JJ, et al. (2012) Gemifloxacin Can Partially Overcome Quinolone Resistance of H. pylori with gyrA Mutation in Taiwan. Helicobacter 17: 210-215.
16. Kim N, Lee JW, Kim JN, Lee DH, Jung HC, et al. (2011) Mutations of Helicobacter pylori in Fluoroquinolone Resistance and the Effect of Point Mutation of gyrA on the Second Line Eradication Therapy in Korea. Gastroenterology 140: S881-S881.
17. Rimbara E, Noguchi N, Kawai T, Sasatsu M (2012) Fluoroquinolone Resistance in Helicobacter pylori: Role of Mutations at Position 87 and 91 of GyrA on the Level of Resistance and Identification of a Resistance Conferring Mutation in GyrB. Helicobacter 17: 36-42.
18. Bago J, Majstorovic K, Belosic-Halle Z, Kucisec N, Bakula V, et al. (2010) Antimicrobial resistance of H. pylori to the outcome of 10-days vs. 7-days Moxifloxacin based therapy for the eradication: a randomized controlled trial. Ann Clin Microbiol Antimicrob 9: 13.
19. Gao W, Cheng H, Hu F, Li J, Wang L, et al. (2010) The evolution of Helicobacter pylori antibiotics resistance over 10 years in Beijing, China. Helicobacter 15: 460-466.
20. Qua CS, Manikam J, Goh KL (2010) Efficacy of 1-week proton pump inhibitor triple therapy as first-line Helicobacter pylori eradication regime in Asian patients: is it still effective 10 years on? J Dig Dis 11: 244-248.
21. Ahmad N, Zakaria WR, Mohamed R (2011) Analysis of antibiotic susceptibility patterns of Helicobacter pylori isolates from Malaysia. Helicobacter 16: 47-51.
22. Ahmad N, Zakaria WR, Abdullah SA, Mohamed R (2009) Characterization of clarithromycin resistance in Malaysian isolates of Helicobacter pylori. World Journal of Gastroenterology 15: 3161-3165.
23. Goh KL, Manikam J, Qua CS (2012) High-dose rabeprazole-amoxicillin dual therapy and rabeprazole triple therapy with amoxicillin and levofloxacin for 2 weeks as first and second line rescue therapies for Helicobacter pylori treatment failures. Alimentary Pharmacology & Therapeutics 35: 1097-1102.
24. Goh KL (2012) Letter: third-line rescue therapy with levofloxacin after failure of two treatments to eradicate Helicobacter pylori infection - author's reply. Alimentary Pharmacology & Therapeutics 35: 1486-1486.
25. Baldwin CM, Keam SJ (2009) Rabeprazole A Review of its Use in the Management of Gastric Acid-Related Diseases in Adults. Drugs 69: 1373-1401.
26. Goh KL, Navaratnam P (2011) High Helicobacter pylori resistance to metronidazole but zero or low resistance to clarithromycin, levofloxacin, and other antibiotics in Malaysia. Helicobacter 16: 241-245.
27. Ho SL, Tan EL, Sam CK, Goh KL (2010) Clarithromycin resistance and point mutations in the 23S rRNA gene in Helicobacter pylori isolates from Malaysia. Journal of Digestive Diseases 11: 101-105.
28. Gerrits MM, van der Wouden EJ, Bax DA, van Zwet AA, van Vliet AH, et al. (2004) Role of the rdxA and frxA genes in oxygen-dependent metronidazole resistance of Helicobacter pylori. J Med Microbiol 53: 1123-1128.
29. Wang LH, Cheng H, Hu FL, Li J (2010) Distribution of gyrA mutations in fluoroquinolone-resistant Helicobacter pylori strains. World J Gastroenterol 16: 2272-2277.
30. Tankovic J, Lascols C, Sculo Q, Petit JC, Soussy CJ (2003) Single and double mutations in gyrA but not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori. Antimicrob Agents Chemother 47: 3942-3944.
31. Corry JEL, Curtis GDW, Baird RM (2003) Handbook of culture media for food microbiology. Amsterdam Boston: Elsevier. xiv, 662 p.p.
32. Han F, Liu S, Ho B, Yan Z, Yan X (2007) Alterations in rdxA and frxA genes and their upstream regions in metronidazole-resistant Helicobacter pylori isolates. Res Microbiol 158: 38-44.
33. Hirata K, Suzuki H, Nishizawa T, Tsugawa H, Muraoka H, et al. (2010) Contribution of efflux pumps to clarithromycin resistance in Helicobacter pylori. J Gastroenterol Hepatol 25 Suppl 1: S75-79.
34. Wuppenhorst N, Lenze F, Ross M, Kist M (2011) Isolation and eradication of a clinical isolate of Helicobacter pylori resistant to five antimicrobials in Germany. J Antimicrob Chemother 66: 222-223.
35. Hall TA (1999) BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symposium: 95-98.
36. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, et al. (2011) MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 28: 2731-2739.
37. Farhana F, Jamaiah I, Rohela M, Aldul-Aziz NM, Nissapatorn V (2009) A ten year (1999-2008) retrospective study of amoebiasis in University Malaya Medical Centre (UMMC), Kuala Lumpur, Malaysia. Tropical Biomedicine 26: 262-266.
38. Binh TT, Shiota S, Nguyen LT, Ho DD, Hoang HH, et al. (2013) The incidence of primary antibiotic resistance of Helicobacter pylori in Vietnam. J Clin Gastroenterol 47: 233-238.
39. Tangmankongworakoon N, Mahachai V, Thong-Ngam D, Vilaichone RK, Tumwasorn S, et al. (2003) Pattern of drug resistant Helicobacter pylori in dyspeptic patients in Thailand. J Med Assoc Thai 86 Suppl 2: S439-444.
40. Lui SY, Yeoh KG, Ho B (2003) Metronidazole-resistant Helicobacter pylori is more prevalent in patients with nonulcer dyspepsia than in peptic ulcer patients in a multiethnic Asian population. J Clin Microbiol 41: 5011-5014.
41. Hansomburana P, Anantapanpong S, Sirinthornpunya S, Chuengyong K, Rojborwonwittaya J (2012) Prevalence of single nucleotide mutation in clarithromycin resistant gene of Helicobacter pylori: a 32-months prospective study by using hybridization real time polymerase chain reaction. J Med Assoc Thai 95 Suppl 3: S28-35.
42. Agudo S, Perez-Perez G, Alarcon T, Lopez-Brea M (2011) Rapid detection of clarithromycin resistant Helicobacter pylori strains in Spanish patients by polymerase chain reaction-restriction fragment length polymorphism. Rev Esp Quimioter 24: 32-36.
43. Lee JW, Kim N, Kim JM, Nam RH, Chang H, et al. (2013) Prevalence of Primary and Secondary Antimicrobial Resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter 18: 206-214.
44. Paul R, Postius S, Melchers K, Schafer KP (2001) Mutations of the Helicobacter pylori genes rdxA and pbp1 cause resistance against metronidazole and amoxicillin. Antimicrobial Agents and Chemotherapy 45: 962-965.
45. Liu Z, Shen J, Zhang L, Shen L, Li Q, et al. (2008) Prevalence of A2143G mutation of H. pylori -23S rRNA in Chinese subjects with and without clarithromycin use history. BMC Microbiol 8: 81.
46. Lee JH, Shin JH, Roe IH, Sohn SG, Kang GH, et al. (2005) Impact of clarithromycin resistance on eradication of Helicobacter pylori in infected adults. Antimicrob Agents Chemother 49: 1600-1603.
47. Khan R, Nahar S, Sultana J, Ahmad MM, Rahman M (2004) T2182C mutation in 23S rRNA is associated with clarithromycin resistance in Helicobacter pylori isolates obtained in Bangladesh. Antimicrob Agents Chemother 48: 3567-3569.
48. Garcia M, Raymond J, Garnier M, Cremniter J, Burucoa C (2012) Distribution of spontaneous gyrA mutations in 97 fluoroquinolone-resistant Helicobacter pylori isolates collected in France. Antimicrob Agents Chemother 56: 550-551.
49. Kese D, Gubina M, Kogoj R, Strasek K, Tepes B (2009) Detection of point mutations in the gyrA gene of Helicobacter pylori isolates in Slovenia. Hepatogastroenterology 56: 925-929.
50. Nishizawa T, Suzuki H, Kurabayashi K, Masaoka T, Muraoka H, et al. (2006) Gatifloxacin resistance and mutations in gyra after unsuccessful Helicobacter pylori eradication in Japan. Antimicrob Agents Chemother 50: 1538-1540.
51. Saravolatz LD, Leggett J (2003) Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones. Clin Infect Dis 37: 1210-1215.